ZCM
CASI

Zebra Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

Zebra Capital Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,118
Closed -$33K – 180
2020
Q4 		$33K Hold
1,118
– – 0.04% 162
2020
Q3 		$17K Sell
1,118
-3,948
-78% -$74.4K 0.03% 164
2020
Q2 		$127K Sell
5,066
-186
-4% -$4.04K 0.18% 183
2020
Q1 		$107K Buy
5,252
+823
+19% +$19.6K 0.17% 179
2019
Q4 		$137K Buy
+4,429
New +$144K 0.12% 251

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
TLP
Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zebra Capital Management's CASI Position: Q1 2021 in Review

Zebra Capital Management sold out of CASI Pharmaceuticals (CASI) in Q1 2021, closing a stake of 1,118 shares — an estimated $33K sold.

Zebra Capital Management first reported a position in CASI in Q4 2019 and held it in 5 quarters. The position peaked at $137K in Q4 2019. 85 funds tracked by Wall St. Rank hold CASI as of Q1 2021.

  • Zebra Capital Management reported no remaining CASI Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Zebra Capital Management sold 1,118 CASI Pharmaceuticals shares in Q1 2021, an estimated $33K.
  • Zebra Capital Management first reported a position in CASI Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Zebra Capital Management's CASI Pharmaceuticals position peaked at $137K in Q4 2019.
  • 85 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2021.

Based on Zebra Capital Management's 13F filing for Q1 2021, filed 17 May 2021.